Literature DB >> 10225908

Cellular immune responses to Neisseria meningitidis in children.

A J Pollard1, R Galassini, E M Rouppe van der Voort, M Hibberd, R Booy, P Langford, S Nadel, C Ison, J S Kroll, J Poolman, M Levin.   

Abstract

There is an urgent need for effective vaccines against serogroup B Neisseria meningitidis. Current experimental vaccines based on the outer membrane proteins (OMPs) of this organism provide a measure of protection in older children but have been ineffective in infants. We postulated that the inability of OMP vaccines to protect infants might be due to age-dependent defects in cellular immunity. We measured proliferation and in vitro production of gamma interferon (IFN-gamma), tumor necrosis factor alpha, and interleukin-10 (IL-10) in response to meningococcal antigens by peripheral blood mononuclear cells (PBMCs) from children convalescing from meningococcal disease and from controls. After meningococcal infection, the balance of cytokine production by PBMCs from the youngest children was skewed towards a TH1 response (low IL-10/IFN-gamma ratio), while older children produced more TH2 cytokine (higher IL-10/IFN-gamma ratio). There was a trend to higher proliferative responses by PBMCs from older children. These responses were not influenced by the presence or subtype of class 1 (PorA) OMP or by the presence of class 2/3 (PorB) or class 4 OMP. Even young infants might be expected to develop adequate cellular immune responses to serogroup B N. meningitidis vaccines if a vaccine preparation can be formulated to mimic the immune stimulus of invasive disease, which may include stimulation of TH2 cytokine production.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10225908      PMCID: PMC115991          DOI: 10.1128/IAI.67.5.2452-2463.1999

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  62 in total

1.  Serotypes of Neisseria meningitidis isolated from patients in Norway during the first six months of 1978.

Authors:  E Holten
Journal:  J Clin Microbiol       Date:  1979-02       Impact factor: 5.948

2.  Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway.

Authors:  G Bjune; E A Høiby; J K Grønnesby; O Arnesen; J H Fredriksen; A Halstensen; E Holten; A K Lindbak; H Nøkleby; E Rosenqvist
Journal:  Lancet       Date:  1991-11-02       Impact factor: 79.321

3.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

4.  Regulation of human IgG subclass production by cytokines. IFN-gamma and IL-6 act antagonistically in the induction of human IgG1 but additively in the induction of IgG2.

Authors:  Y Kawano; T Noma; J Yata
Journal:  J Immunol       Date:  1994-12-01       Impact factor: 5.422

5.  Construction of a multivalent meningococcal vaccine strain based on the class 1 outer membrane protein.

Authors:  P Van Der Ley; J T Poolman
Journal:  Infect Immun       Date:  1992-08       Impact factor: 3.441

6.  Complex of meningococcal group B polysaccharide and type 2 outer membrane protein immunogenic in man.

Authors:  W D Zollinger; R E Mandrell; J M Griffiss; P Altieri; S Berman
Journal:  J Clin Invest       Date:  1979-05       Impact factor: 14.808

7.  Cross-antigenicity and immunogenicity between capsular polysaccharides of group C Neisseria meningitidis and of Escherichia coli K92.

Authors:  M P Glode; J B Robbins; T Y Liu; E C Gotschlich; I Orskov; F Orskov
Journal:  J Infect Dis       Date:  1977-01       Impact factor: 5.226

8.  Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba.

Authors:  G V Sierra; H C Campa; N M Varcacel; I L Garcia; P L Izquierdo; P F Sotolongo; G V Casanueva; C O Rico; C R Rodriguez; M H Terry
Journal:  NIPH Ann       Date:  1991-12

9.  Production, characterization and control of MenB-vaccine "Folkehelsa": an outer membrane vesicle vaccine against group B meningococcal disease.

Authors:  J H Fredriksen; E Rosenqvist; E Wedege; K Bryn; G Bjune; L O Frøholm; A K Lindbak; B Møgster; E Namork; U Rye
Journal:  NIPH Ann       Date:  1991-12

10.  Identification of T cell epitopes occurring in a meningococcal class 1 outer membrane protein using overlapping peptides assembled with simultaneous multiple peptide synthesis.

Authors:  E J Wiertz; J A van Gaans-van den Brink; H Gausepohl; A Prochnicka-Chalufour; P Hoogerhout; J T Poolman
Journal:  J Exp Med       Date:  1992-07-01       Impact factor: 14.307

View more
  10 in total

1.  Cellular Immune Responses in Humans Induced by Two Serogroup B Meningococcal Outer Membrane Vesicle Vaccines Given Separately and in Combination.

Authors:  Fredrik Oftung; Gro Ellen Korsvold; Audun Aase; Lisbeth M Næss
Journal:  Clin Vaccine Immunol       Date:  2016-04-04

2.  Improved method to calculate the antibody avidity index.

Authors:  C T Perciani; P S Peixoto; W O Dias; F S Kubrusly; M M Tanizaki
Journal:  J Clin Lab Anal       Date:  2007       Impact factor: 2.352

3.  Age and disease related changes in intestinal bacterial populations assessed by cell culture, 16S rRNA abundance, and community cellular fatty acid profiles.

Authors:  M J Hopkins; R Sharp; G T Macfarlane
Journal:  Gut       Date:  2001-02       Impact factor: 23.059

4.  T-cell-stimulating protein A elicits immune responses during meningococcal carriage and human disease.

Authors:  Karen Robinson; Karl G Wooldridge; Damien B Wells; Amal Hasan; Ian Todd; Adrian Robins; Richard James; Dlawer A A Ala'Aldeen
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

5.  Neisserial immunoglobulin A1 protease induces specific T-cell responses in humans.

Authors:  Anastasios Tsirpouchtsidis; Robert Hurwitz; Volker Brinkmann; Thomas F Meyer; Gaby Haas
Journal:  Infect Immun       Date:  2002-01       Impact factor: 3.441

6.  Attenuation of monocyte proinflammatory cytokine responses to Neisseria meningitidis in children by erythropoietin.

Authors:  C Schultz; J Zimmer; C Härtel; J Rupp; P Temming; T Strunk
Journal:  Clin Exp Immunol       Date:  2008-09-08       Impact factor: 4.330

7.  Mucosal vaccination against serogroup B meningococci: induction of bactericidal antibodies and cellular immunity following intranasal immunization with NadA of Neisseria meningitidis and mutants of Escherichia coli heat-labile enterotoxin.

Authors:  Frances Bowe; Ed C Lavelle; Edel A McNeela; Christine Hale; Simon Clare; Beatrice Arico; Marzia M Giuliani; Aaron Rae; Alan Huett; Rino Rappuoli; Gordon Dougan; Kingston H G Mills
Journal:  Infect Immun       Date:  2004-07       Impact factor: 3.441

Review 8.  How the Knowledge of Interactions between Meningococcus and the Human Immune System Has Been Used to Prepare Effective Neisseria meningitidis Vaccines.

Authors:  R Gasparini; D Panatto; N L Bragazzi; P L Lai; A Bechini; M Levi; P Durando; D Amicizia
Journal:  J Immunol Res       Date:  2015-08-17       Impact factor: 4.818

9.  Characterization of humoral and cellular immune responses elicited by meningococcal carriage.

Authors:  K Robinson; K R Neal; C Howard; J Stockton; K Atkinson; E Scarth; J Moran; A Robins; I Todd; E Kaczmarski; S Gray; I Muscat; R Slack; D A A Ala'Aldeen
Journal:  Infect Immun       Date:  2002-03       Impact factor: 3.441

10.  Characterisation of the Immunomodulatory Effects of Meningococcal Opa Proteins on Human Peripheral Blood Mononuclear Cells and CD4+ T Cells.

Authors:  Claire Jones; Manish Sadarangani; Susan Lewis; Isabelle Payne; Muhammad Saleem; Jeremy P Derrick; Andrew J Pollard
Journal:  PLoS One       Date:  2016-04-25       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.